IP Library Granted Patent US 12679866
Granted Patent B2
US 12679866 · App. 17/753,919 · Granted Jul 14, 2026

Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide

Inventor: Michiko Koga (Shizuoka, JP)
C07K7/06A61P35/00C07K16/44A61K38/00A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679866
App. No.
17/753,919
Granted
Jul 14, 2026
Kind
B2
Abstract

An object of the present invention is to provide an efficient method of cell fusion, and to provide a method of killing cancer cells by cell fusion. The object can be solved by (1) a polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1 to 8, or (2) a polypeptide comprising an amino acid sequence, in which 1 to 4 amino acids are deleted, substituted, inserted, and/or added in an amino acid sequence of SEQ ID NOs: 1 to 8, and having a cell fusion activity.

Claims (8)

1 . A polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1 to 8, wherein the N-terminus of SEQ ID NO:2 is methylated.

2 . The polypeptide according to claim 1 , wherein the polypeptide comprises an amino acid sequence selected from SEQ ID Nos: 1 and 3-8, and the N-terminus of the polypeptide is methylated.

3 . A polynucleotide encoding the polypeptide according to claim 1 .

4 . A vector comprising the polynucleotide according to claim 3 .

5 . A transformant comprising the vector according to claim 4 .

6 . A cell fusion agent comprising the polypeptide according to claim 1 , as an active ingredient.

7 . A pharmaceutical composition comprising the polypeptide according to claim 1 , as an active ingredient.

8 . A method for treating Lung cancer, comprising a step of administrating to a subject in need of such treatment a therapeutically effective amount of the polypeptide according to claim 1 .